Last year, sales of obesity treatments surpassed Keytruda, the immune anticancer drug that had long held the top sales ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Jan 12 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of Merck & Co's (MRK.N), opens new tab blockbuster immunotherapy Keytruda in combination with ...

Merck’s oncology drug Keytruda will outpace all Rx brands by global sales in 2028, as Roche rides its biologics stable to become the frontrunner among pharma companies, according to a five-year World ...

Merck & Co. raised its sales forecast amid increased demand for Keytruda, its blockbuster cancer treatment that now accounts for 40% of revenue, and a surprisingly strong result from its controversial ...

The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey (Reuters) - Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with ...

Former President Jimmy Carter credits the new cancer drug Keytruda for shrinking his brain tumors completely. It's one more victory for the newest class of cancer drugs that empower the immune system ...

Matthew Herper covers medical innovation — both its promise and its perils. Merck said a new formulation of the best-selling drug, Keytruda, appears to deliver similar blood levels of the medicine ...